Change 5-day change 1-year change 3-year change Capi.($)
-16.67%-16.67% - - 4.97K
+0.11%-3.03%+20.33%+10.20% 216B
-1.21%-3.49%-4.21%-20.37% 142B
+2.15%-0.53%-17.07%+39.58% 138B
-0.60%+0.11%-50.27%+2.10% 74.53B
+0.45%-2.47%+16.67%+19.29% 52.34B
+1.18%-0.33%-16.45%-13.29% 50.28B
-0.27%-0.96%+25.32%+24.16% 41.93B
-1.25%-2.88%+39.27%+49.27% 40.06B
+0.55%+0.26%-0.31%+6.70% 32.69B
Average -1.58%-0.52%+1.47%+13.07% 87.63B
Weighted average by Cap. +0.17%-1.16%+0.47%+10.74%
Logo SpectraScience, Inc.
SpectraScience, Inc. is focused on developing its WavSTAT Optical Biopsy System (WavSTAT). The WavSTAT employs a risk technology that optically illuminates tissue in real-time to distinguish between normal and pre-cancerous or cancerous tissue. The Company has developed a technology platform to determine if tissue is normal, pre-cancerous or cancerous, without the need for a physical biopsy. The WavSTAT4 Optical Biopsy System operates by using cool, safe ultraviolet (UV) laser light to optically illuminate and analyze tissue, enabling the physician to make a diagnosis during endoscopy when screening for cancer and, if warranted, to begin immediate treatment during the same procedure. The WavSTAT4 uses laser-induced auto-fluorescence to obtain spectral information from tissue at the suspected site. The system is classified as a non-significant risk device, which transmits low-level UV laser light energy through an optical fiber to the tissue through the working channel of an endoscope.
Employees
-